GlassScriptPhysician profile
Hsiu Su
NPI 1710486725
$4,052.80
in general payments reported to CMS, 2019-2025
20 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.34 · 2022: $32.91 · 2023: $808 · 2024: $1,547 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.56 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,327.48 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $609.69 | 2021-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $372.57 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $206.87 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.02 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $164.83 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $141.11 | 2024 | Veozah |
| Radius Health, INC. | $128.86 | 2023-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $128.52 | 2023-2025 | Verquvo, Lagevrio |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $120.70 | 2023-2025 | Zoryve, Livalo |
| Exact Sciences Corporation | $110.19 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $87.88 | 2023-2025 | |
| Novo Nordisk INC | $66.93 | 2022-2025 | Rybelsus, Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $31.57 | 2024 | |
| Sumitomo Pharma America, INC. | $22.75 | 2025 | Gemtesa |
| Dexcom, INC. | $22.29 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $17.12 | 2025 | |
| Abbvie INC. | $15.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiu Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.